PRACTICAL GUIDE | 2026
When the rebate math works, when it doesn’t, and what sponsors learn too late.
By Julio G. Martinez-Clark
CEO, bioaccess®
Last verified: September 2026 | General information only—not legal or regulatory advice. Rules change frequently; confirm the strategy with qualified regulatory counsel.
Latin America vs. Australia for first-in-human trials is the comparison sponsors actually run. Australia is bioaccess®’s real FIH competitor — sponsors arrive already sold on offshore FIH and ask us to argue the other side. So here is the honest version: Australia’s genuine advantages, where it falls short, where Latin America wins, and when each region is the right call.
Definitions first. FIH means first-in-human — the first testing of a device or drug in people. Australia’s R&D Tax Incentive (RDTI) is a government tax offset for eligible research and development: a 43.5% refundable offset for companies with aggregated turnover under A$20 million, meaning the credit is paid in cash even to companies with no tax liability. TGA is Australia’s Therapeutic Goods Administration, the national regulator.
What does Australia offer FIH sponsors?
Australia’s headline advantage is real money. The RDTI provides a 43.5% refundable tax offset on eligible R&D expenditure for companies with aggregated turnover below A$20 million (larger companies receive a non-refundable offset starting at 38.5%, scaling with R&D intensity). For a cash-constrained startup, a cash refund on nearly half of eligible spend is a powerful funding mechanism. Clinical trials are a core use case: biotech companies routinely claim trial costs, and the program is jointly administered by AusIndustry and the Australian Taxation Office.
Beyond the rebate: English-language operations, mature TGA-regulated early-phase units, world-class hospitals in Sydney and Melbourne, and a global reputation for high-quality data that regulators everywhere recognize. Foreign companies can access the incentive, typically through an Australian subsidiary or local structure, provided the R&D is conducted in Australia — though eligibility turns on who incurs the expenditure and who owns the resulting IP, a frequent focus of audits.
Where does Australia fall short?
Cost before the rebate is high — early-phase unit fees, investigator costs, and operational overhead run well above Latin American levels, which is why the incentive exists at all. Recruitment is the deeper problem: Australia’s population is small and trial competition for patients is intense, so enrollment can drag. And approvals are not the smooth path sponsors expect — one US sponsor told us it lost three years in Australia because it could not get approval. That is one company’s experience, not a national statistic, but it is the kind of story that makes sponsors ask us for the comparison in the first place.
Where does Latin America win?
- Cost: typically 30–50%+ savings versus the US — lower per-patient and operational costs, with no rebate paperwork required to realize them.
- Speed: activation in as little as four weeks in the fast corridor (Panama, Chile, El Salvador, Costa Rica) versus the eight-month timelines sponsors report elsewhere.
- Recruitment: deep investigator access and large treatment-naïve populations; enrollment risk — the binding constraint in most FIH programs — is structurally lower.
- Time zones: US-aligned working hours, versus a 10–16 hour gap with Australia.
- Data acceptance: ICH-GCP data from qualified LATAM sites is routinely usable with FDA under 21 CFR 812.28 (devices) and 21 CFR 312.120 (drugs).
| Dimension | Australia | Latin America |
|---|---|---|
| Net-cost lever | 43.5% refundable R&D tax offset (eligible entities, turnover < A$20M) | 30–50%+ lower base costs vs. the US; no claim process |
| Activation | Months; delays reported by sponsors | As little as 4 weeks in the fast corridor |
| Recruitment | Difficult; small population, high trial competition | Strong investigator access; large patient pools |
| Language | English | Spanish / Portuguese; bilingual CRO staff standard |
| Regulator | TGA | INVIMA, COFEPRIS, ANVISA, ANMAT, ISP, DIGEMID |
| US time-zone gap | 10–16 hours | Aligned |
When should you choose Australia over Latin America?
Honestly: when the rebate math genuinely works for you. If you already have — or will build — an Australian entity conducting eligible R&D, the 43.5% cash offset can beat LATAM’s base-cost advantage on paper. Australia also fits sponsors who specifically value TGA oversight, whose therapeutic area matches an Australian unit’s deep expertise, or whose investors simply prefer the jurisdiction. Run both models with real quotes before deciding — rebate-on-paper versus all-in cost are different numbers.
When should you choose Latin America?
When speed is the critical path. When recruitment risk — not budget — is what keeps you up at night. When you are a startup that needs the lowest absolute cash outlay, not a future tax refund. And when you want physician-level local execution in your time zone, with FDA-usable GCP data at the end of it.
Frequently asked questions
Q: Can a US company claim Australia’s R&D tax incentive for a clinical trial?
A: Yes, if the R&D is conducted in Australia — typically through an Australian subsidiary or local arrangement. Eligibility depends on who incurs the expenditure and effective ownership of the resulting IP, which auditors scrutinize.
Q: Is Australia cheaper than Latin America after the 43.5% rebate?
A: Sometimes on paper. The rebate applies to eligible expenditure; Australia’s pre-rebate costs are substantially higher, and the refund arrives after filing. Compare all-in, time-adjusted cost with real quotes — not headline rates.
Q: Will FDA accept FIH data from both Australia and Latin America?
A: Yes, under the same rules: GCP-compliant data from qualified sites. Geography is not the criterion in either case.
Q: Can we run FIH in both regions?
A: Yes — staged or parallel multi-region programs are common for de-risking timelines and enrollment. Each region’s data must meet the same GCP standard.
Q: How long do approvals take in Australia?
A: Timelines vary by study and pathway; sponsors have reported significant delays, including multi-year cases. Verify current expectations with a local regulatory advisor for your specific program.
Q: Latin America vs. Australia for first-in-human trials — what is the simplest decision rule?
A: If your binding constraint is absolute cash and speed to data, Latin America usually wins. If you have an Australian structure and the rebate math closes the gap, Australia deserves a real quote. Never decide on reputation alone — decide on quotes, clocks, and enrollment risk.
Latin America vs. Australia for first-in-human trials is not a contest with one winner. It is a trade: a world-class rebate compensating for world-class costs and recruitment friction, against lower base costs, faster activation, and deeper enrollment access. Know which constraint binds your program — and choose accordingly.
Talk with bioaccess® about your Latin America FIH strategy
Considering Australia, Latin America, or both? Send us your synopsis and we will model the two paths side by side — real startup clocks, real enrollment assumptions, real budget anatomy — so you decide on numbers, not narratives.
Talk with bioaccess® about your Latin America FIH strategy
References
- WilmerHale Launch (April 2026): Australia’s R&D Tax Incentive — 43.5% refundable offset for eligible entities with aggregated turnover below A$20 million — https://launch.wilmerhale.com/research/blog/20260413-dont-let-australias-r-d-tax-incentive-trigger-unintended-us-international-tax-cost-sharing-issues
- Opportuna Legal: Australia’s R&D Tax Incentive — general overview for clinical trials — https://www.opportunalegal.com.au/single-post/australia-s-r-d-tax-incentive-a-general-overview-for-clinical-trials
- bioaccess® client experience with Australia benchmarking and LATAM FIH programs, 2021–2026. Last verified: September 2026.
Leave a Reply